543 related articles for article (PubMed ID: 8751209)
21. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of serum hyaluronate concentrations in patients with alcoholic liver disease.
Tsutsumi M; Urashima S; Takase S; Ueshima Y; Tsuchishima M; Shimanaka K; Kawahara H
Alcohol Clin Exp Res; 1997 Dec; 21(9):1716-21. PubMed ID: 9438536
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
24. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
[TBL] [Abstract][Full Text] [Related]
25. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C.
Ikura Y; Morimoto H; Johmura H; Fukui M; Sakurai M
Am J Gastroenterol; 1996 Jul; 91(7):1367-73. PubMed ID: 8677997
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
27. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
28. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
30. Therapy of hepatitis C: re-treatment with alpha interferon.
Alberti A; Chemello L; Noventa F; Cavalletto L; De Salvo G
Hepatology; 1997 Sep; 26(3 Suppl 1):137S-142S. PubMed ID: 9305679
[TBL] [Abstract][Full Text] [Related]
31. Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: relation to disease progression and effect of interferon alpha.
Yoshioka K; Kakumu S; Hayashi H; Shinagawa T; Wakita T; Ishikawa T; Itoh Y; Takayanagi M
Am J Gastroenterol; 1991 Oct; 86(10):1495-9. PubMed ID: 1928044
[TBL] [Abstract][Full Text] [Related]
32. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
33. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection].
Ortarık Z; Toyran A; Sen S; Mart Kömürcü SZ; Güvener E
Mikrobiyol Bul; 2011 Apr; 45(2):296-305. PubMed ID: 21644073
[TBL] [Abstract][Full Text] [Related]
35. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study.
Castilla A; Camps-Bansell J; Civeira MP; Prieto J
Am J Gastroenterol; 1993 Feb; 88(2):233-9. PubMed ID: 8424427
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of relative low-dose interferon treatment for patients with chronic hepatitis C.
Hayashi J; Kishihara Y; Tani Y; Yamaji K; Nakashima K; Ikematsu H; Kashiwagi S
Fukuoka Igaku Zasshi; 1994 Jul; 85(7):211-8. PubMed ID: 8070751
[TBL] [Abstract][Full Text] [Related]
37. [Histological evaluation of the liver and response to interferon in chronic hepatitis C].
Yoshida H; Iwabuchi S; Murayama M; Uchikoshi T
Nihon Rinsho; 1994 Jul; 52(7):1763-8. PubMed ID: 8078200
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
Castilla A; Prieto J; Fausto N
N Engl J Med; 1991 Apr; 324(14):933-40. PubMed ID: 1900574
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of measurement of a novel basement membrane-associated collagen levels in serum].
Nakabayashi H; Takamatsu S; Nakano H; Kosaka M; Ito S
Rinsho Byori; 1995 Jul; 43(7):691-5. PubMed ID: 7674541
[TBL] [Abstract][Full Text] [Related]
40. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.
Kasahara A; Hayashi N; Hiramatsu N; Oshita M; Hagiwara H; Katayama K; Kato M; Masuzawa M; Yoshihara H; Kishida Y
Hepatology; 1995 Feb; 21(2):291-7. PubMed ID: 7843696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
